Celldex Therapeutics(CLDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CLDX Celldex Therapeutics

Post-Market Trading 11-05 16:23:28 EST

25.43

+0.04

+0.16%

盘后26.01

+0.58+2.28%

16:16 EST

High25.72	Low24.43	Vol1.25M
Open25.34	D1 Closing25.39	Amplitude5.06%
Mkt Cap1.69B	Tradable Cap1.68B	Total Shares66.29M
T/O31.41M	T/O Rate1.89%	Tradable Shares66.10M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"CLDX","market":"US","secType":"STK","nameCN":"Celldex Therapeutics","latestPrice":25.43,"timestamp":1730840400000,"preClose":25.39,"halted":0,"volume":1248727,"hourTrading":{"tag":"盘后","latestPrice":26.01,"preClose":25.43,"latestTime":"16:16 EST","volume":16475,"amount":418964.57142500003,"timestamp":1730841384614},"delay":0,"floatShares":66104324,"shares":66287596,"eps":-2.679796,"marketStatus":"Post-Market Trading","change":0.04,"latestTime":"11-05 16:23:28 EST","open":25.34,"high":25.715,"low":24.43,"amount":31414915.685031,"amplitude":0.05061,"askPrice":30,"askSize":750,"bidPrice":24.85,"bidSize":50,"shortable":3,"etf":0,"ttmEps":-2.679796,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1730854800000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":515304000000,"exchange":"NASDAQ","adjPreClose":25.39,"preHourTrading":{"tag":"盘前","latestPrice":25.43,"preClose":25.39,"latestTime":"09:29 EST","volume":103,"amount":2619.200081,"timestamp":1730816999999},"postHourTrading":{"tag":"盘后","latestPrice":26.01,"preClose":25.43,"latestTime":"16:16 EST","volume":16475,"amount":418964.57142500003,"timestamp":1730841384614},"volumeRatio":0.942879,"impliedVol":0.8014,"impliedVolPercentile":0.9246},"requestUrl":"/m/hq/s/CLDX/wiki","defaultTab":"wiki","newsList":[{"id":"2479643204","title":"Celldex Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2479643204","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479643204?lang=en_us&edition=fundamental","pubTime":"2024-10-29 01:23","pubTimestamp":1730136180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLDX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 28, 2024 13:23 ET (17:23 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDX"],"gpt_icon":0},{"id":"2479436479","title":"Celldex selloff creates buying opportunity, says Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2479436479","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479436479?lang=en_us&edition=fundamental","pubTime":"2024-10-29 00:05","pubTimestamp":1730131532,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Yatin Suneja notes that Celldex (CLDX) presented full data from the Phase 2 trial of barzolvolimab in two common forms of chroni...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/celldex-selloff-creates-buying-opportunity-says-guggenheim?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/celldex-selloff-creates-buying-opportunity-says-guggenheim?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CLDX"],"gpt_icon":0},{"id":"2478989106","title":"Celldex Therapeutics (NASDAQ:CLDX) pulls back 6.1% this week, but still delivers shareholders fantastic 57% CAGR over 5 years","url":"https://stock-news.laohu8.com/highlight/detail?id=2478989106","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478989106?lang=en_us&edition=fundamental","pubTime":"2024-10-28 18:55","pubTimestamp":1730112916,"startTime":"0","endTime":"0","summary":"It hasn't been the best quarter for Celldex Therapeutics, Inc.  shareholders, since the share price has fallen 30% in that time. But that does not change the realty that the stock's performance has been terrific, over five years. In that time, the share price has soared some 863% higher!So we don't think the recent decline in the share price means its story is a sad one. Only time will tell if there is still too much optimism currently reflected in the share price. While the returns over the last 5 years have been good, we do feel sorry for those shareholders who haven't held shares that long, because the share price is down 39% in the last three years. Anyone who held for that rewarding ride would probably be keen to talk about it.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/celldex-therapeutics-nasdaq-cldx-pulls-105516615.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MNQmain","IE00BGHQF748.EUR","SQQQ","QID","QLD",".IXIC","IE00B64PRP62.GBP","LU2095319765.USD","NDAQ","CLDX","BK4112","NQmain","BK4585","IE00B3QW5Z07.USD","BK4139","BK4588","TQQQ","LU2210149790.SGD","PSQ","IE00BKPKM429.USD","LU2210150020.SGD"],"gpt_icon":1},{"id":"2478122949","title":"BRIEF-Celldex Announces Barzolvolimab Met All Primary And Secondary Endpoints With High Statistical Significance In Positive Phase 2 Study In Chronic Inducible Urticaria","url":"https://stock-news.laohu8.com/highlight/detail?id=2478122949","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478122949?lang=en_us&edition=fundamental","pubTime":"2024-10-28 15:42","pubTimestamp":1730101323,"startTime":"0","endTime":"0","summary":"Oct 28 (Reuters) - Celldex Therapeutics Inc   :   * CELLDEX ANNOUNCES BARZOLVOLIMAB MET ALL PRIMARY AND SECONDARY ENDPOINTS WITH HIGH STATISTICAL SIGNIFICANCE IN POSITIVE PHASE 2 STUDY IN CHRONIC INDUCIBLE URTICARIA((Reuters.Briefs@thomsonreuters.com))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDX"],"gpt_icon":0},{"id":"2478909326","title":"Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints With High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria","url":"https://stock-news.laohu8.com/highlight/detail?id=2478909326","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478909326?lang=en_us&edition=fundamental","pubTime":"2024-10-27 05:43","pubTimestamp":1729979000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241026:nTUA5WX03J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLDX","BK4139"],"gpt_icon":0},{"id":"2478990965","title":"Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria","url":"https://stock-news.laohu8.com/highlight/detail?id=2478990965","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478990965?lang=en_us&edition=fundamental","pubTime":"2024-10-27 05:43","pubTimestamp":1729978980,"startTime":"0","endTime":"0","summary":"First to demonstrate clinical benefit in patients with chronic inducible urticaria (CIndU)in large, randomized, placebo-controlled study Favorable safety and tolerability Plan to advance CIndU into Ph","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/26/2969702/24180/en/Celldex-Announces-Barzolvolimab-Met-All-Primary-and-Secondary-Endpoints-with-High-Statistical-Significance-in-Positive-Phase-2-Study-in-Chronic-Inducible-Urticaria.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTT","BK4084","CLDX","BK4213","SD","BK4139"],"gpt_icon":0},{"id":"2478124980","title":"BRIEF-Celldex Announces Upcoming Late Breaking Oral Presentation Of 12 Week Results From Barzolvolimab Phase 2 Study In Chronic Inducible Urticaria At Acaai 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2478124980","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478124980?lang=en_us&edition=fundamental","pubTime":"2024-10-25 21:17","pubTimestamp":1729862266,"startTime":"0","endTime":"0","summary":"Oct 25 (Reuters) - Celldex Therapeutics Inc   :   * CELLDEX ANNOUNCES UPCOMING LATE BREAKING ORAL PRESENTATION OF 12 WEEK RESULTS FROM BARZOLVOLIMAB PHASE 2 STUDY IN CHRONIC INDUCIBLE URTICARIA AT ACAAI 2024Source text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDX"],"gpt_icon":0},{"id":"2478989545","title":"Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results From Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at Acaai 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2478989545","media":"THOMSON REUTERS","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478989545?lang=en_us&edition=fundamental","pubTime":"2024-10-25 20:01","pubTimestamp":1729857674,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241025:nTUA7GSR2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLDX","BK4139"],"gpt_icon":0},{"id":"2478943989","title":"Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2478943989","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478943989?lang=en_us&edition=fundamental","pubTime":"2024-10-25 20:01","pubTimestamp":1729857660,"startTime":"0","endTime":"0","summary":"HAMPTON, N.J., Oct. 25, 2024  -- Celldex Therapeutics, Inc.  announced today that 12 week results from the Company’s Phase 2 clinical trial of barzolvolimab in two of the most common forms of chronic inducible urticaria —cold urticaria  and symptomatic dermographism —will be presented in a late breaking oral presentation at theAmerican College of Allergy, Asthma & Immunology's  Annual Scientific Meeting being held in Boston October 24-28, 2024.About Celldex Therapeutics, Inc.Celldex is a clinical stage biotechnology company leading the science at the intersection of mast cell biology and the development of transformative therapeutics for patients. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Visit www.celldex.com.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/93p.vbTX5JaFZLixROfDUA--~B/aD04MDk7dz0zMzc1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/029600e15d50813f95bb9ea14198f6a4","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/93p.vbTX5JaFZLixROfDUA--~B/aD04MDk7dz0zMzc1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/029600e15d50813f95bb9ea14198f6a4"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/celldex-announces-upcoming-breaking-oral-120100912.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SD","BK4213","CLDX","BK4139"],"gpt_icon":0},{"id":"2475816616","title":"Celldex Therapeutics, Inc. (CLDX): Hedge Funds’ Hidden Gem in Small-Cap Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2475816616","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475816616?lang=en_us&edition=fundamental","pubTime":"2024-10-16 06:10","pubTimestamp":1729030201,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Most Promising Small-Cap Stocks According to Hedge Funds. In this article, we are going to take a look at where Celldex Therapeutics, Inc.  stands against other most promising small-cap stocks.Small-Cap Stocks are Expected to Offer Higher Returns in 2025. Small-cap stocks are offering a myriad of opportunities to investors and are expected to go higher. On September 25, Greg Tuorto, Goldman Sachs asset management portfolio manager, appeared in an interview onYahoo Financeto discuss his thesis on small-cap stocks.There have been several tailwinds for small-cap stocks, which may have been ignored previously. However, now that the economy is stabilizing, investors may find a variety of undervalued names in the healthcare and technology sectors especially.Tuorto further added that small-cap stocks have been underperforming for three years, however, in 2024, there is a lot of pent-up opportunity in this area. A year from now, small-cap stocks are expected ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/kjZNLgkTopCUY4vUPPWfaA--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/9e40b782fa1d5f681b2ffb080d276cc9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/kjZNLgkTopCUY4vUPPWfaA--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/9e40b782fa1d5f681b2ffb080d276cc9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/celldex-therapeutics-inc-cldx-hedge-221001319.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","QLD","TQQQ","NQmain","PSQ","QID","MNQmain",".IXIC","SQQQ","CLDX"],"gpt_icon":1},{"id":"2473177882","title":"Citigroup Initiates Celldex Therapeutics at Buy With $70 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2473177882","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473177882?lang=en_us&edition=fundamental","pubTime":"2024-10-07 20:31","pubTimestamp":1728304275,"startTime":"0","endTime":"0","summary":"Celldex Therapeutics (CLDX) has an average buy rating and a price target range of $44 to $90, according to analysts polled by Capital IQ.(MT Newswires covers equity, commodity and economic research fr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CLDX"],"gpt_icon":0},{"id":"2473173283","title":"Celldex Therapeutics Inc : Citigroup Initiates Coverage With Buy Rating; Price Target $70","url":"https://stock-news.laohu8.com/highlight/detail?id=2473173283","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473173283?lang=en_us&edition=fundamental","pubTime":"2024-10-07 18:36","pubTimestamp":1728297364,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241007:nFWN3LJ07C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLDX","BK4139"],"gpt_icon":0},{"id":"2473735711","title":"Celldex (CLDX) Gets a Buy from Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2473735711","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473735711?lang=en_us&edition=fundamental","pubTime":"2024-10-07 18:26","pubTimestamp":1728296808,"startTime":"0","endTime":"0","summary":"Citi analyst David Lebowitz initiated coverage with a Buy rating on Celldex (CLDX – Research Report) today and set a price target of $70.00. The co...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/celldex-cldx-gets-a-buy-from-citi?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/celldex-cldx-gets-a-buy-from-citi?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLDX","BK4139"],"gpt_icon":0},{"id":"2472368169","title":"Celldex started by Goldman Sachs at neutral, lack of catalysts cited","url":"https://stock-news.laohu8.com/highlight/detail?id=2472368169","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472368169?lang=en_us&edition=fundamental","pubTime":"2024-10-01 05:50","pubTimestamp":1727733041,"startTime":"0","endTime":"0","summary":"Celldex Therapeutics'  coverage was initiated at neutral by Goldman Sachs, due in part to concerns about the market opportunity for its drug candidate barzolvolimab in chronic urticaria and a lack of meaningful near-term catalysts. The investment bank said “strong statistical significance” in Phase 2 results for the drug and the company replicating the study’s design for Phase 3 while adding loaded doses “give us confidence that barzo can succeed in Phase 3 and demonstrate best-in-class efficacy.” Goldman Sachs added, however, that the drug's side effects could affect utilization by clinicians and patients.  The bank also noted that “potential approvals for Xolair biosimilars, Dupixent, and remibrutinib in the next 1-2 years will likely confine barzo exclusively to 2L+, which we believe is a smaller opportunity than CLDX projected.” Goldman Sachs set a price target of $45 for the stock.","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1155610132/image_1155610132.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1155610132/image_1155610132.jpg"],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4154797-celldex-started-by-goldman-sachs-at-neutral-lack-of-catalysts-cited","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["CLDX"],"gpt_icon":0},{"id":"2471795805","title":"Goldman Sachs Initiates Coverage on Celldex Therapeutics With Neutral Rating, $45 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2471795805","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471795805?lang=en_us&edition=fundamental","pubTime":"2024-09-30 19:25","pubTimestamp":1727695531,"startTime":"0","endTime":"0","summary":"Celldex Therapeutics (CLDX) has an average rating of Buy and price targets ranging from $44 to $90, according to analysts polled by Capital IQ.(MT Newswires covers equity, commodity and economic resea","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CLDX"],"gpt_icon":0},{"id":"2471820037","title":"Hold Rating on Celldex Therapeutics Amid Drug Development Prospects and Competitive Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2471820037","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471820037?lang=en_us&edition=fundamental","pubTime":"2024-09-30 16:15","pubTimestamp":1727684117,"startTime":"0","endTime":"0","summary":"Richard Law CFA, an analyst from Goldman Sachs, has initiated a new Hold rating on Celldex (CLDX). Richard Law CFA has given his Hold rating due to...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/hold-rating-on-celldex-therapeutics-amid-drug-development-prospects-and-competitive-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/hold-rating-on-celldex-therapeutics-amid-drug-development-prospects-and-competitive-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLDX"],"gpt_icon":0},{"id":"2470703377","title":"Celldex Therapeutics Cut to Peer Perform From Outperform by Wolfe Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2470703377","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470703377?lang=en_us&edition=fundamental","pubTime":"2024-09-27 17:55","pubTimestamp":1727430900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLDX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 27, 2024 05:55 ET (09:55 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDX"],"gpt_icon":0},{"id":"2470077259","title":"Wolfe Research Downgrades Celldex Therapeutics to Peer Perform From Outperform","url":"https://stock-news.laohu8.com/highlight/detail?id=2470077259","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470077259?lang=en_us&edition=fundamental","pubTime":"2024-09-27 17:29","pubTimestamp":1727429345,"startTime":"0","endTime":"0","summary":"Celldex Therapeutics (CLDX) has an average rating of buy and price targets ranging from $44 to $90, according to analysts polled by Capital IQ.(MT Newswires covers equity, commodity and economic resea","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CLDX"],"gpt_icon":0},{"id":"2470754135","title":"CLDX Stock Down Despite Upbeat Long-Term Data From Urticaria Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2470754135","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470754135?lang=en_us&edition=fundamental","pubTime":"2024-09-26 22:28","pubTimestamp":1727360880,"startTime":"0","endTime":"0","summary":"Shares of Celldex Therapeutics CLDX lost 12.1% on Wednesday due to unsatisfactory 52-week safety data from a mid-stage study of its investigational candidate, barzolvolimab, which is being developed for treating chronic spontaneous urticaria .CSU is a type of skin disease, characterized by the sudden appearance of hives  without an identifiable trigger. The exact cause is often unknown, but it can be linked to immune system dysfunction, where the body mistakenly triggers allergic reactions. While CSU is not life-threatening, it can significantly impact a person’s quality of life due to persistent itching and discomfort.The phase II study evaluated the efficacy and safetyof three dosing regimens of barzolvolimab  compared with placebo in 208 CSU patients, who remain symptomatic despite antihistamine therapy to determine the optimal dosing strategy.Please note that Celldex had previously reported achieving the primary efficacy endpoint of the mid-stage study, observing a statistically si","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/YaeP6YMQifV47czKTk1orA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/045ba7ae9e660e2a91686804eef7ab55","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/YaeP6YMQifV47czKTk1orA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/045ba7ae9e660e2a91686804eef7ab55"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cldx-stock-down-despite-upbeat-142800634.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ANIP","KRYS","FULC","BK4007","CLDX"],"gpt_icon":0},{"id":"2470782025","title":"Celldex (CLDX) Receives a Buy from TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2470782025","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470782025?lang=en_us&edition=fundamental","pubTime":"2024-09-26 19:35","pubTimestamp":1727350526,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Yaron Werber maintained a Buy rating on Celldex (CLDX – Research Report) today. The company’s shares closed yesterday at $36.02. W...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/celldex-cldx-receives-a-buy-from-td-cowen?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/celldex-cldx-receives-a-buy-from-td-cowen?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TD","CLDX","BK4566","COWN","BK4207","BK4585","BK4139","BK4127"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.celldex.com","stockEarnings":[{"period":"1week","weight":-0.0922},{"period":"1month","weight":-0.1716},{"period":"3month","weight":-0.2423},{"period":"6month","weight":-0.3839},{"period":"1year","weight":-0.0227},{"period":"ytd","weight":-0.3598}],"compareEarnings":[{"period":"1week","weight":-0.019},{"period":"1month","weight":-0.0055},{"period":"3month","weight":0.0913},{"period":"6month","weight":0.1017},{"period":"1year","weight":0.3108},{"period":"ytd","weight":0.1988}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.578947,"avgChangeRate":0.133197},{"month":2,"riseRate":0.421053,"avgChangeRate":-0.003124},{"month":3,"riseRate":0.473684,"avgChangeRate":0.006506},{"month":4,"riseRate":0.473684,"avgChangeRate":-0.001523},{"month":5,"riseRate":0.289474,"avgChangeRate":-0.020325},{"month":6,"riseRate":0.487179,"avgChangeRate":0.148994},{"month":7,"riseRate":0.410256,"avgChangeRate":-0.015387},{"month":8,"riseRate":0.358974,"avgChangeRate":-0.028768},{"month":9,"riseRate":0.307692,"avgChangeRate":-0.023053},{"month":10,"riseRate":0.487179,"avgChangeRate":0.003931},{"month":11,"riseRate":0.538462,"avgChangeRate":0.056491},{"month":12,"riseRate":0.447368,"avgChangeRate":-0.007128}],"exchange":"NASDAQ","name":"Celldex Therapeutics","nameEN":"Celldex Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Celldex Therapeutics(CLDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Celldex Therapeutics(CLDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Celldex Therapeutics,CLDX,Celldex Therapeutics股票,Celldex Therapeutics股票老虎,Celldex Therapeutics股票老虎国际,Celldex Therapeutics行情,Celldex Therapeutics股票行情,Celldex Therapeutics股价,Celldex Therapeutics股市,Celldex Therapeutics股票价格,Celldex Therapeutics股票交易,Celldex Therapeutics股票购买,Celldex Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Celldex Therapeutics(CLDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Celldex Therapeutics(CLDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}